Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
11.26
-0.47 (-4.01%)
At close: Jun 5, 2026, 4:00 PM EDT
11.28
+0.02 (0.18%)
After-hours: Jun 5, 2026, 4:15 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$576,775
Profits / Employee
-$516,533
Market Cap
327.42M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Abeona Therapeutics | 226 |
| Artiva Biotherapeutics | 104 |
| Verastem | 102 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 59 |
| Atea Pharmaceuticals | 55 |
| Zura Bio | 40 |
ENTA News
- 1 day ago - Enanta Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 8 days ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 25 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Business Wire
- 25 days ago - Enanta Pharmaceuticals Earnings release: Q2 2026 - Filings
- 25 days ago - Enanta Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - Business Wire
- 7 weeks ago - Enanta announces first participant dosed in Phase 1 trial of EDP-978 - TheFly
- 7 weeks ago - Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - Business Wire